Why is $ADCT moving today? · SEC 8-K archive

$ADCT SEC Filing Alert & Real-Time AI Stock Impact Analysis

T0 SEO archive for $ADCT: filings appear instantly. AI score, direction and bullet analysis unlock publicly after 4 hours (VIP sees them live).

← All archive signals

FAQ: $ADCT filing catalyst

Why did $ADCT trigger an AI stock catalyst alert?

$ADCT triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: ADC Therapeutics Reports Strong ZYNLONTA Clinical Data in ASH 2026 Abstracts. Key points: - Phase 1b LOTIS-7 data shows 88.7% ORR and 75.3% CR for ZYNLONTA + glofitamab in 97 r/r DLBCL patients. - Phase 2 monotherapy trial in MZL achieved 93% ORR and 74.4% CR with a 2-year PFS rate of 90.8%. - Phase 3 data demonstrated statistically significant PFS improvement over R-GemOx (HR 0.73, P=0.0083).

How did $ADCT stock react after the SEC filing?

After the SEC 8-K for $ADCT, observed market reaction: T0 price $1.72. Past moves do not guarantee future results.

Where can I get real-time $ADCT SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ADCT via Telegram and the VIP Web Terminal from €10/month.

$ADCT

$ADCT – ADC Therapeutics Reports Strong ZYNLONTA Clinical Data in ASH 2026 Abstracts

ADC Therapeutics SA

2026-11-04 00:00:00 UTC · SEC 8-K · All $ADCT

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Phase 1b LOTIS-7 data shows 88.7% ORR and 75.3% CR for ZYNLONTA + glofitamab in 97 r/r DLBCL patients.
Phase 2 monotherapy trial in MZL achieved 93% ORR and 74.4% CR with a 2-year PFS rate of 90.8%.
Phase 3 data demonstrated statistically significant PFS improvement over R-GemOx (HR 0.73, P=0.0083).

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →